JoVE Logo
Faculty Resource Center

Sign In

Assays for the Identification of Novel Antivirals against Bluetongue Virus

DOI :

10.3791/50820-v

October 11th, 2013

October 11th, 2013

13,695 Views

1Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, 2Molette Laboratory for Drug Discovery, Department of Chemistry and Biochemistry, Auburn University

Three assays, including the cytopathic effect (CPE)-based assay, dose-response assay and Time-of-Addition (ToA) assay have been developed, optimized, validated and utilized to identify novel antivirals against Bluetongue virus (BTV), as well as to determine the possible Mechanism-of-Action (MoA) for newly identified antivirals.

-- Views

Related Videos

article

Viral Concentration Determination Through Plaque Assays: Using Traditional and Novel Overlay Systems

article

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

article

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

article

Qualitative and Quantitative Assays for Detection and Characterization of Protein Antimicrobials

article

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

article

Development and Identification of a Novel Subpopulation of Human Neutrophil-derived Giant Phagocytes In Vitro

article

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

article

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

article

Rapid, Safe, and Simple Manual Bedside Nucleic Acid Extraction for the Detection of Virus in Whole Blood Samples

article

Identification of Coding and Non-coding RNA Classes Expressed in Swine Whole Blood

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved